Shiyu Han
Research Subjects
Shiyu Han has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Caifeng Xu
College of Nursing, Changchun University of Chinese Medicine, Changchun, China
1 shared publication - Changgeng Ruan
Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Chaowei Fu
School of Public Health, Fudan University, China
1 shared publication - Dan Wang
Department of Endocrinology, Metabolism and Gastroenterology, Third Affiliated Clinical Hospital to Changchun University of Chinese Medicine, Changchun 130117, Jilin, China
1 shared publication - Depei Wu
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Fang Wang
Chongqing Three Gorges Medical College
1 shared publication
Latest Publications
- Open Access
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
Demands for sexual health education among middle school students in China
Objective: According to the World Health Organization, premarital sexuality, unplanned pregnancy, and the spread of sexually transmitted diseases are major problems in adolescent sexual health. In China, adolescents generally lack sexual health knowledge and contraceptive ability while the sexual...
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
Open AccessDemands for sexual health education among middle school students in China
Objective: According to the World Health Organization, premarital sexuality, unplanned pregnancy, and the spread of sexually transmitted diseases are major problems in adolescent sexual health. In China, adolescents generally lack sexual health knowledge and contraceptive ability while the sexual...
- Open Access
- 15 February 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-16
Signature of m5C-Related lncRNA for Prognostic Prediction and Immune Responses in Pancreatic Cancer
Background. Pancreatic cancer (PC) has a high mortality and dismal prognosis, predicting to be the second most lethal malignancy. 5-Methylcytosine (m5C) and long noncoding RNAs (lncRNAs) are both crucial in the prognostic outcome and immunotherapeutic effect for PC patients. Therefore, we aimed to create an m5C-related lncRNA signature (m5C-LS) for PC patients prognosis and treatment. Methods. Clinicopathological information and RNAseq data were acquired from The Cancer Genome Atlas (TCGA) database. Pearsons correlation analysis was used to extract m5C-related lncRNAs in PC. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox analyses were adopted to build an m5C-LS. KaplanMeier (K-M), principal component analysis (PCA), and nomogram were utilized to assess model accuracy. In addition, we explored the models possible immunotherapeutic responses and drug sensitivity targets. Results. Three m5C-related lncRNAs were finally established to construct the risk signature, which has a good and independent predictive ability for PC patients. Based on the m5C-LS, patients were classified into the low- and high-m5C-LS group, with the latter having a worse prognosis. Furthermore, the m5C-LS allowed us to better discriminate the immunotherapeutic responses of PC patients in different subgroups. Conclusions. Our study constructed an m5C-LS and established a nomogram model that accurately predicted the prognosis of PC patients, as well as provides promising immunotherapeutic strategies in the future.
- 15 February 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-16
Open AccessSignature of m5C-Related lncRNA for Prognostic Prediction and Immune Responses in Pancreatic Cancer
Background. Pancreatic cancer (PC) has a high mortality and dismal prognosis, predicting to be the second most lethal malignancy. 5-Methylcytosine (m5C) and long noncoding RNAs (lncRNAs) are both crucial in the prognostic outcome and immunotherapeutic effect for PC patients. Therefore, we aimed to create an m5C-related lncRNA signature (m5C-LS) for PC patients prognosis and treatment. Methods. Clinicopathological information and RNAseq data were acquired from The Cancer Genome Atlas (TCGA) database. Pearsons correlation analysis was used to extract m5C-related lncRNAs in PC. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox analyses were adopted to build an m5C-LS. KaplanMeier (K-M), principal component analysis (PCA), and nomogram were utilized to assess model accuracy. In addition, we explored the models possible immunotherapeutic responses and drug sensitivity targets. Results. Three m5C-related lncRNAs were finally established to construct the risk signature, which has a good and independent predictive ability for PC patients. Based on the m5C-LS, patients were classified into the low- and high-m5C-LS group, with the latter having a worse prognosis. Furthermore, the m5C-LS allowed us to better discriminate the immunotherapeutic responses of PC patients in different subgroups. Conclusions. Our study constructed an m5C-LS and established a nomogram model that accurately predicted the prognosis of PC patients, as well as provides promising immunotherapeutic strategies in the future.
- Open Access
- 1 August 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (8) , 1486-1491
Circulating Heme Oxygenase-1 and Complement Activation in Transplant-Associated Thrombotic Microangiopathy
- 1 August 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (8) , 1486-1491
Open AccessCirculating Heme Oxygenase-1 and Complement Activation in Transplant-Associated Thrombotic Microangiopathy